The Additional Hetero Ring Is One Of The Cyclos In A Polycyclo Ring System Patents (Class 514/337)
  • Publication number: 20040171645
    Abstract: (R/S)-(±)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof and/or (S)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof are used for the manufacture of a medicament for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders.
    Type: Application
    Filed: January 26, 2004
    Publication date: September 2, 2004
    Inventors: Gerd Bartoszyk, Herman Russ, Christoph Seyfried, Frank Weber
  • Patent number: 6780879
    Abstract: Taxanes having a carbonate substituent at C(7), a hydroxy substituent at C(10), and a range of C(2), C(9), C(14), and side chain substituents.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: August 24, 2004
    Assignee: FSU Research Foundation, Inc.
    Inventor: Robert A. Holton
  • Patent number: 6780859
    Abstract: This invention relates to novel benzofuran and dihydrobenzofuran compounds, pharmaceutical compositions containing such compounds, and methods of treating beta-3 adrenoreceptor-mediated conditions with such compositions.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: August 24, 2004
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Gaetan H. Ladouceur, William R. Schoen, Michael J. Burke
  • Publication number: 20040162318
    Abstract: The present invention relates to novel benzofuran derivatives and analogs, as well as compositions containing the same and to the use thereof for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the hepatitis C virus.
    Type: Application
    Filed: October 31, 2003
    Publication date: August 19, 2004
    Inventors: Ashis K. Saha, Christopher J. Burns, Alfred M. Del Vecchio, Thomas R. Bailey, Jason A. Reinhardt, Bheemashankar A. Kulkarni, Thomas H. Faitg, Hao Feng, Susan R. Rippin, Charles W. Blackledge, David J. Rys, Thomas A. Lessen, John Swestock, Yijun Deng, Theodore J. Nitz
  • Patent number: 6777430
    Abstract: A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and depression.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: August 17, 2004
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Peter Blurton, Frank Burkamp, Susan Koon-Fung Cheng, Stephen Robert Fletcher, Angus Murray MacLeod, Daniel Spinks, Monique Bodil Van Niel
  • Publication number: 20040157841
    Abstract: Mono-acylated o-phenylendiamines derivatives of formula I 1
    Type: Application
    Filed: February 3, 2004
    Publication date: August 12, 2004
    Inventors: Georg Fertig, Frank Herting, Manfred Kubbies, Anja Limberg, Ulrike Reiff, Michael Weidner
  • Publication number: 20040152736
    Abstract: A series of compounds represented by the structural formulas 1 2
    Type: Application
    Filed: September 25, 2003
    Publication date: August 5, 2004
    Inventors: Samuel Chackalamannil, Mariappan V. Chelliah, Yan Xia
  • Publication number: 20040147525
    Abstract: Compounds of the formula (I) below, or pharmacologically acceptable salts, esters or other derivatives thereof: 1
    Type: Application
    Filed: July 22, 2003
    Publication date: July 29, 2004
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Tomio Kimura, Kazumasa Aoki, Akira Nakao
  • Patent number: 6767916
    Abstract: Disclosed are novel chalcone derivatives having the formula (I). These compounds possess antiproliferative activity, and are useful for the manufacture of a medicament for the treatment or prevention of neoplasms, particularly those located in the uterus, ovary or breast. The compounds of the invention may also be useful in the manufacture of a medicament for the treatment or prevention of menopausal disorders and osteoporosis.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: July 27, 2004
    Assignee: Indena S.p.A.
    Inventors: Ezio Bombardelli, Piero Valenti
  • Publication number: 20040138284
    Abstract: Indol-3-yl derivatives of the general formula I 1
    Type: Application
    Filed: January 5, 2004
    Publication date: July 15, 2004
    Inventors: Matthias Wiesner, Simon Goodman, Rudolf Gottschlich
  • Publication number: 20040138266
    Abstract: The present invention relates to a process for the preparation of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman, the enantiomers and its salts, characterised in that 5-(4-fluorophenyl)pyridine-3-carbaldehyde is reacted directly with aminomethylchroman or its salts under reducing conditions to give 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman, and the latter is, if desired, converted into one of its physiologically acceptable salts by treatment with an acid.
    Type: Application
    Filed: October 27, 2003
    Publication date: July 15, 2004
    Inventors: Heinz-Hermann Bokel, Steffen Neuenfeld, Ludwig Gantzert, Ralf Knierieme, Elke Simon, Ralf Devant, Udo Helm, Helmut Reubold
  • Publication number: 20040138267
    Abstract: Taxanes having a carbonate substituent at C(7), a hydroxy substituent at C(10), and a range of C(2), C(9), C(14), and side chain substituents.
    Type: Application
    Filed: December 22, 2003
    Publication date: July 15, 2004
    Applicant: FSU Research Foundation Inc.
    Inventor: Robert A. Holton
  • Publication number: 20040138142
    Abstract: The invention relates to new carbohydrate derivatives of paclitaxel and docetaxel with increased solubility in water as compared to the parent compounds, paclitaxel and docetaxel These derivatives are produced from naturally occurring precursor molecules which upon hydrolysis yield these natural precursors and the original paclitaxel and docetaxel molecules. The present invention also related to the composition and the use of such derivatives for cancer therapy. These derivatives may also be used in antifungal or antiviral therapy.
    Type: Application
    Filed: January 9, 2003
    Publication date: July 15, 2004
    Inventor: Michel Page
  • Publication number: 20040138265
    Abstract: The invention concerns novel carboxamides of formula (I) wherein A is (A1), (A2), (A3), (A4), (A5); Q is (Q1), (Q2), (Q3), (Q4), (Q5), (Q6); R1 is CH2 R2, CH2CH═CHR2, CH═C═CHR2 or COR3; R2 is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, COOC1-C4alkyl, COOC3-C6alkenyl, COOC3-C6alkynyl or CN; R3 is C1-C6alkyl, C1-C6alkyl substituted by halogen, C1-C6alkoxy or C1-C6haloalkoxy; or is C1-C6alkylthio, C1-C6haloalkylthio, C1-C6alkoxy, C1-C6haloalkoxy; C3-C6alkenyloxy or C3-C6haloalkenyloxy; C3-C6haloalkenyloxy; C3-C6alkynyloxy or C3-C6haloalkynyloxy; R4 is methyl, CF2Cl, CF3, CF2H, CFH2, Cl or Br, R5 is methyl, CF3, CH2OCH3 or CH2OCF3; R6 is hydrogen, fluoro, CF3 or methyl; R7 is hydrogen, methyl or halogen; and Z is phenyl, halophenyl, C5-C7cycloalkyl, C5-C7acycloalkyl substituted by C1-C3alkyl, C1C3haloalkyl or halogen, or a group of the form —CHR8—CH2—CHR9R10 wherein R8, R9 and R10 are independently of each other C1-C3alkyl.
    Type: Application
    Filed: January 12, 2004
    Publication date: July 15, 2004
    Inventors: Harald Walter, Stephan Trah
  • Patent number: 6759420
    Abstract: The present invention is directed to new compounds for the inhibition of blood clotting proteins and factor Xa activity, and more particularly, to arylalkanoyl derivatives of the formula (I): wherein R(1), R(2), R(3), R(4), R(5), R(6a), and R(6b) have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (I), to methods of inhibiting factor Xa activity and of inhibiting blood clotting, to the use of the compounds of formula (I) in the treatment and prophylaxis of diseases whcih can be treated or prevented by the inhibition of factor Xa activity, such as cardiovascular or thromboembolic diseases, and to the use of the compounds of formula (I) in the preparation of medicaments to be applied in such diseases.
    Type: Grant
    Filed: December 28, 1999
    Date of Patent: July 6, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Elisabeth Defossa, Uwe Heinelt, Otmar Klingler, Gerhard Zoller, Hans Matter, Fahad A. Al-Obeidi, Armin Walser, Peter Wildgoose
  • Publication number: 20040122055
    Abstract: Taxanes having a carbonate substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.
    Type: Application
    Filed: November 24, 2003
    Publication date: June 24, 2004
    Applicant: FSU Research Foundation Inc.
    Inventor: Robert A. Holton
  • Publication number: 20040116440
    Abstract: Bombesin receptor antagonists are provided which are useful for the diagnosis, prevention, or treatment of male sexual dysfunction in humans and animals, female sexual dysfunction in humans and animals, anxiety and panic disorders, social phobia, depression, psychoses, sleeping disorders, memory impairment, pulmonary hypertension, lung repair and lung development disorders, cancer including prostate cancer and pancreatic cancer, hepatic porphyria, gastrointestinal secretory disturbances, gastrointestinal disorders including colitis, Crohn's disease and inflammatory bowel disease, emesis, anorexia, pain, seasonal affective disorders, feeding disorders, or pruritus.
    Type: Application
    Filed: December 4, 2003
    Publication date: June 17, 2004
    Inventors: Michael Higginbottom, Martyn Clive Pritchard, Herman Thijs Stock
  • Patent number: 6750245
    Abstract: Taxanes having a carbamoyloxy substituent at C(7), a hydroxy substituent at C(10, and a range of C(2), C(9), C(14), and side chain substituents.
    Type: Grant
    Filed: February 6, 2002
    Date of Patent: June 15, 2004
    Assignee: FSU Research Foundation, Inc.
    Inventor: Robert A. Holton
  • Patent number: 6743808
    Abstract: 4-Aryl-1-(indanmethyl, dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl)piperidine, -tetrahydropyridine or -piperazine compounds of general formula (I), wherein one of X and Y is CH2 and the other one is CH2, O or S; Z is N, C, CH or COH; Ar is an optionally substituted aryl group; R1 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, acyl, thioacyl, alkylsulfonyl, trifluoromethylsulfonyl, arylsulfonyl, a group R9VCO— where V is O or S and R9 is alkyl or aryl, or a group R10R11NCO— or R10R11NCS— wherein R10 and R11 are hydrogen, alkyl or aryl, or R10 and R11 are linked to form a ring; R2 is hydrogen, alkyl, cycloalkyl or cycloalkylalkyl or R1 and R2 are linked to form a ring; R3-R5 are hydrogen, halogen, alkyl, alkylcarbonyl, phenylcarbonyl, alkoxy, alkylthio, hydroxy, alkylsulfonyl, cyano, trifluoromethyl, cycloalkyl, cycloalkylalkyl or nitro; R6 and R7 are hydrogen or alkyl or they are linked to constitute 3-7-membered ring; R8 is hydrogen or alkyl; h
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: June 1, 2004
    Assignee: H. Lundbeck A/S
    Inventors: Jens Kristian Perregaard, John Willie Stenberg, Bitten Hansen
  • Publication number: 20040096397
    Abstract: Sulfonated diarylrhodamine compounds are useful as fluorescent labels of nucleosides, nucleotides, polynucleotides, and polypeptides. The compounds find particular application in the area of fluorescent nucleic acid analysis, e.g., automated DNA sequencing and fragment analysis, detection of probe hybridization in hybridization arrays, detection of nucleic acid amplification products, and the like.
    Type: Application
    Filed: June 24, 2003
    Publication date: May 20, 2004
    Applicant: Applera Corporation
    Inventors: Steven M. Menchen, Scott C. Benson, Joe Y.L. Lam, Weiguo Zhen, Daqing Sun, Barnett B. Rosenblum, Shaheer H. Khan, Meng Taing
  • Patent number: 6737427
    Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: May 18, 2004
    Assignee: Genaera Corporation
    Inventors: Yuhong Zhou, Roy C. Levitt, Nicholas C. Nicolaides, Steve Jones, Mike McLane
  • Publication number: 20040087624
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: December 10, 2003
    Publication date: May 6, 2004
    Inventors: Gerard Martin Paul Giblin, Stephen Vernon Frye, Susan Roomans
  • Publication number: 20040087625
    Abstract: The invention relates to triamide MTP/ApoB inhibitors of the formula 1 1
    Type: Application
    Filed: August 13, 2003
    Publication date: May 6, 2004
    Applicant: Pfizer Inc
    Inventors: Peter Bertinato, Brian S. Bronk, Alan E. Blize, Hengmiao Cheng, Jin Li, Hiep Huatan, Clive Mason
  • Publication number: 20040082601
    Abstract: This invention relates to anti-inflammatory compounds, methods of making such compounds and methods of using such compounds having the following structure: 1
    Type: Application
    Filed: October 21, 2003
    Publication date: April 29, 2004
    Inventors: Malcolm K. Scott, Pauline J. Sanfilippo, Louis J. Fitzpatrick, Richard Cordova, Kevin Pan, Joseph Meschino
  • Patent number: 6727239
    Abstract: A compound of the formula wherein the substituents are defined as in the specification and their pharmaceutically acceptable salts having NOS and ROS activity.
    Type: Grant
    Filed: April 2, 2003
    Date of Patent: April 27, 2004
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
    Inventors: Pierre-Etienne Chabrier de Lassauniere, Serge Auvin, Jerry Harnett, Dominique Pons, Gérard Ulibarri, Dennis Bigg
  • Patent number: 6723739
    Abstract: A compound of the formula or a pharmaceutically acceptable salt or solvate thereof. Also provided by the invention are methods of use of the above compounds, and processes for the preparation thereof.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: April 20, 2004
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey A. Dodge, Charles A. Frolik, Terry D. Lindstrom, Charles W. Lugar, III
  • Publication number: 20040072872
    Abstract: Taxanes having an ester substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.
    Type: Application
    Filed: October 1, 2003
    Publication date: April 15, 2004
    Applicant: FSU Research Foundation, Inc.
    Inventor: Robert A. Holton
  • Patent number: 6716850
    Abstract: Compounds of the formula I: where; R1 is O, S; R2 is an optionally substituted nitrogen-containing heterocycle, wherein the nitrogen is located at the 2 position relative to the (thio)urea bond; R3 is H, C1-C3 alkyl, R4-R7 are independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, haloC1-C6 alkyl, C1-C6 alkanoyl, haloC1-C6 alkanoyl, C1-C6 alkoxy, haloC1-C6 alkoxy, C1-C6 alkyloxy-C1-C6 alkyl, haloC1-C6 alkyloxy-C1-C6 alkyl hydroxy-C1-C6 alkyl, amino-C1-C6 alkyl, carboxy-C1-C6 alkyl, cyano-C1-C6 alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto; X is —(CHR8)n-—D—(CHR8)m—; D is —NR9—, —O—, —S—, —S(═O)— or —S(═O)2—; R8 is independently H, C1-C3 alkyl, halo substitutedC1-C3alkyl; R9 is H, C1-C3 alkyl; n and m are independently 0, 1 or 2; and prodrugs and pharmaceutically acceptable salts thereof, have utility as inhibitors of HIV-1 reverse transcriptase, particular
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: April 6, 2004
    Assignee: Medivir AB
    Inventors: Stefan Lindström, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Odén, Lotta Naeslund
  • Publication number: 20040053990
    Abstract: Radicicol derivatives represented by the following formula (I) having tyrosine kinase inhibition activity or pharmacologically acceptable salts thereof: 1
    Type: Application
    Filed: July 30, 2003
    Publication date: March 18, 2004
    Applicant: KYOWA HAKKO KOGYO CO., LTD
    Inventors: Yoji Ino, Nobuyoshi Amishiro, Mayumi Miyata, Chikara Murakata, Harumi Ogawa, Tadakazu Akiyama, Shiro Akinaga, Shiro Soga, Yukimasa Shiotsu
  • Patent number: 6706757
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: March 16, 2004
    Assignee: Wyeth
    Inventors: Lynne Padilla Greenblatt, Michael Gerard Kelly
  • Patent number: 6703383
    Abstract: One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: March 9, 2004
    Assignee: Sepracor, Inc.
    Inventors: Xinhe Wu, Brian M. Aquila, Liming Shao, Heike Radeke, Gregory D. Cuny, James R. Hauske, Roger L. Xie
  • Patent number: 6699860
    Abstract: This invention is related to novel di-substituted aminomethyl chroman derivatives which are useful in the treatment of beta-3 receptor-mediated conditions.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: March 2, 2004
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Gaetan H. Ladouceur, William H. Bullock, Steven R. Magnuson, Stephen J. O'Connor, Roger A. Smith, Quanrong Shen, Qingjie Liu, Ning Su, Emil J. Velthuisen, Ann-Marie Campbell, Paul P. Ehrlich
  • Publication number: 20040039019
    Abstract: Selected anthranilamide pyridinamines of general formula I 1
    Type: Application
    Filed: June 19, 2003
    Publication date: February 26, 2004
    Applicant: Schering AG
    Inventors: Andreas Huth, Martin Krueger, Ludwig Zorn, Stuart Ince, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • Patent number: 6696484
    Abstract: Pharmaceutical compositions and methods for treating androgen related disorders. The pharmaceutical compositions may include a 5&agr;-reductase inhibitor, such as natural and synthetic flavanoids, catechols, curcumin-related substances, quinones, catechins, particularly epigallocatechin derivatives, fatty acids, and the salts, esters, analogues, pro-drugs, isomers, racemic mixtures, or derivatives of any of the foregoing. The use of testosterone (or DHT) combinations with the aforementioned 5&agr;-reductase inhibitor compounds is also contemplated.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: February 24, 2004
    Assignee: University of Chicago Office of Technology and Intellectual Property
    Inventors: Shutsung Liao, Richard Hiipakka
  • Patent number: 6696470
    Abstract: A compound of the formula: and its pharmaceutically effective salts, wherein R1 and R2 are independently selected from the following: (a) hydrogen, halo, R5—, C2-6 alkenyl, C2-6 alkynyl, hydroxy-R5—, R5—O—R5—, or the like; (b) Ar—, Ar—R5—, Ar—C2-6 alkenyl, Ar—C2-6 alkynyl, Ar—O—, Ar—O—R5— or the like; (c) R5—C(O)—, —NO2, cyano, NH2—C(O)—, R5—NH—C(O)—, (R5)2—N—C(O)—, Ar—C(O)— or the like; and (d) R5—C(O)—NH—, Ar—C(O)—NH— or the like; wherein Ar is optionally substituted aryl or heteroaryl such as phenyl and pyridyl; and wherein R5 is optionally halo-substituted C1-6 alkyl; R3 is selected from the following: (e) cyano, formyl, tetrazolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, R5—C(O)—, C2-6 alkenyl-C(O)—, C2-6 alkynyl-C(O)—, R5—C(O)—R5—, or the
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: February 24, 2004
    Assignee: Pfizer Inc.
    Inventors: Akiyoshi Kawai, Makoto Kawai
  • Patent number: 6689797
    Abstract: The present invention relates to compounds of formula (I): in which R1 represents a hydrogen or halogen atom, or a group CF3; R2 and R3 represent, independently, a hydrogen atom or a methyl group; n and n′ each represent, independently, 0 or 1; * represents the positions of attachment; A represents N or CH; X represents a sulfur or oxygen atom; R4 and R5 represent, independently, a hydrogen atom or a (C1-C6) alkyl group; and also their salts or solvates, to a method for the preparation thereof and to the pharmaceutical compositions containing them.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: February 10, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Marco Baroni, Bernard Bourrie, Rosanna Cardamone, Pierre Casellas
  • Patent number: 6689798
    Abstract: The present invention provides novel benzofuran derivatives represented by the following formula (I) or salts thereof: wherein Py is a 2-, 3-, or 4-pyridyl group and R is a substituted or unsubstituted phenyl group or a substituted or unsubstituted aromatic heterocyclic group. The present invention also relates to inhibitors of steroid 17&agr;-hydroxylase and/or steroid C17-20 lyase and pharmaceutical compositions containing a benzofuran derivative of the above formula (I), or the salt.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: February 10, 2004
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Shin'ichi Shimada, Shin Nomoto, Masayuki Okue, Ken'ichi Kimura, Junji Nakamura, Yoshikazu Ikeda, Takeko Takada
  • Patent number: 6689799
    Abstract: The present invention relates to ester derivatives of 1,4-dihydropyridine-5-carboxylic acid of formula (I) wherein R1, R2 and R3 may be a coumarin group. These compounds possess an anti-viral activity. Most of the anti-viral compounds known in the art are nucleoside-derivatives. Various viruses become resistent against these. Because the compounds according to the invention are not nucleoside-derivatives, they form a suitable alternative. The invention also relates to a method of preparing the anti-viral substances according to the invention.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: February 10, 2004
    Assignee: Rephartox
    Inventors: Geert Jan Sterk, Jan Fetze Van Der Werf
  • Publication number: 20040023984
    Abstract: The present invention is directed to analogs of galanthamine of the structure 1
    Type: Application
    Filed: March 26, 2003
    Publication date: February 5, 2004
    Applicant: BONNIE DAVIS
    Inventors: Bonnie M. Davis, Madeleine M. Joullie
  • Patent number: 6686348
    Abstract: A compound of formula (I): wherein: R1 represents hydrogen, halogen, alkyl or alkoxy, X represents oxygen, sulphur or NR wherein R represents hydrogen or alkyl, A represents any one of the groups described in the description, their isomers and addition salts thereof with a pharmaceutically acceptable acid or base and medicinal products containing the same are useful as metalloprotease inhibitor.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: February 3, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Guillaume De Nanteuil, Alain Benoist, Philippe Pastoureau, Massimo Sabatini, John Hickman, Alain Pierre, Gordon Tucker
  • Patent number: 6683095
    Abstract: A novel 3-hydroxychromen-4-one derivative, pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase (“CDK”) is disclosed. Further, a process for preparing the compound and a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. is disclosed comprising the compound as an active component together with pharmaceutically acceptable carriers.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: January 27, 2004
    Assignee: LG Life Sciences Ltd.
    Inventors: Chang-Yong Hong, Jin-Ho Lee, Tae-Sik Park, Jong-Hyun Kim, Sei-Hyun Choi, Sook-Kyung Yoon, Hyun-Ho Chung, Ho-Sun Son, Eunice Eun-Kyeong Kim, Seong-Gu Ro, Shin-Wu Jeong, Dong-Myung Kim
  • Publication number: 20040014788
    Abstract: Use of compounds being combined selective dopamine D2 receptor antagonists and 5-HT1A receptor agonists, in particular (R)-(−)-2-[5-4 fluorophenyl)-3-pyridylmethyl-aminomethyl]-chromane or a physiologically acceptable salt thereof or N-(4′-fluoro-3-biphenylmethyl)-N-2-(3-cycanophenoxy-ethyl)-amine or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in veterinary medicine for the treatment of self directed traumatic disorders associated with behavioral stressors, compulsive disorders associated with behavioral stressors and/or anxiety disorders associated with behavioral stressors.
    Type: Application
    Filed: May 13, 2003
    Publication date: January 22, 2004
    Inventor: Gerd Bartoszyk
  • Patent number: 6680332
    Abstract: Disclosed is a method for treating a disorder responsive to the positive modulation of AMPA receptors in animals suffering therefrom, comprising administering to an animal in need thereof a compound of Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is NH2, NHR, and NHCOR; Z is O and S; and R1, R2, R3, R4, and X are defined herein. These compounds can be used as cognitive enhancers, for the treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, AIDS associated dementia and Down's syndrome as well as for the treatment of schizophrenia and myoclonus. Also disclosed are pharmaceutical compositions useful for treating disorders responsive to the positive modulation of AMPA receptors, and novel compounds of Formula I.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: January 20, 2004
    Assignee: Euro-Celtique S.A.
    Inventors: Christopher S. Konkoy, David B. Fick, Sui Xiong Cai, Nancy C. Lan, John F. W. Keana
  • Publication number: 20040006105
    Abstract: Heterocyclic-substituted compounds of the formula 1
    Type: Application
    Filed: June 9, 2003
    Publication date: January 8, 2004
    Inventors: Samuel Chackalamannil, Mariappan V. Chelliah, Yan Xia
  • Patent number: 6673833
    Abstract: Taxanes having a heterosubstituted acetate substituent at C(7), a hydroxy substituent at C(10), and a range of C(2), C(9), C(14), and side chain substituents.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: January 6, 2004
    Assignee: FSU Research Foundation, Inc.
    Inventor: Robert A. Holton
  • Publication number: 20040002502
    Abstract: The present invention relates to novel pharmaceutical compositions based on a new anticholinergic 1 and heterocyclic compounds 2, processes for preparing them and their use in the treatment of respiratory complaints.
    Type: Application
    Filed: April 8, 2003
    Publication date: January 1, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Helmut Meissner, Gerd Morschhaeuser, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Christopher John Montague Meade, Michel Pairet
  • Publication number: 20030236220
    Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.
    Type: Application
    Filed: November 8, 2002
    Publication date: December 25, 2003
    Applicant: Genaera Corporation
    Inventors: Yuhong Zhou, Roy C Levitt, Nicholas C Nicolaides, Steve Jones, Mike McLane
  • Publication number: 20030236279
    Abstract: The invention provides compounds of Formula I: 1
    Type: Application
    Filed: February 10, 2003
    Publication date: December 25, 2003
    Inventors: Daniel Patrick Walker, David W. Piotrowski, Eric Jon Jacobsen, Brad A. Acker, Jason K. Myers, Vincent E. Groppi
  • Patent number: 6664274
    Abstract: The present invention provides compounds of formula I and a method of inhibiting the reuptake of serotonin, antagonizing the 5-HT1A receptor and antagonizing the 5-HT2A receptor which comprises administering to a subject in need of such treatment an effective amount of a compound of formula I.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: December 16, 2003
    Assignee: Eli Lilly and Company
    Inventors: Sidney Xi Liang, Yao-Chang Xu
  • Patent number: 6664275
    Abstract: Taxanes having a heterosubstituted acetate substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: December 16, 2003
    Assignee: FSU Research Foundation, Inc.
    Inventor: Robert A. Holton